CHECKPOINT INHIBITOR IMMUNO-ONCOLOGY DRUGS
A GLOBAL MARKET ACCESS LANDSCAPE
Researched and developed exclusively
for HTAi 2017
Checkpoint inhibitor immuno-oncology drugs are making headlines for breaking new ground. This report provides a baseline understanding of the marketing authorizations and market access these drugs have gained in major markets.
Please complete the form below to view the webinar recording.